Literature DB >> 11832375

Human insulin release processes measured by intraportal sampling.

Niels Pørksen1, Thorbjørn Grøfte, Jacob Greisen, Anette Mengel, Claus Juhl, Johannes D Veldhuis, Ole Schmitz, Martin Rössle, Hendrik Vilstrup.   

Abstract

Insulin is secreted as a series of punctuated secretory bursts superimposed on variable basal insulin release. The contribution of these secretory bursts to overall insulin secretion has been estimated on the basis of peripheral vein sampling in humans to encompass > or =75% of overall insulin release. A similar contribution of the pulsatile mode of release was inferred in a canine model by use of portal vein sampling. The primary regulation of insulin secretion is through perturbation of the mass and frequency of these secretory bursts. The mode of delivery of insulin into the circulation seems important for insulin action; therefore, physiological conditions that alter the pattern of insulin release may affect insulin action through this mechanism. Transhepatic intraportal shunt in humans may provide access to portal vein samples, thus potentially improving the sensitivity of detecting and quantitating the frequency, mass, and amplitude of secretory bursts along with basal release and the regularity of these variables. To establish the insulin-secretory mechanism in nondiabetic humans by the use of portal vein sampling, we here assessed the mass, frequency, amplitude, and overall contribution of pulsatile insulin secretion by deconvolution analysis of portal vein insulin profiles. We find that, in nondiabetic humans fasted overnight, the portal vein insulin concentration oscillates at a periodicity of 4.1 +/- 0.2 min/pulse and with secretory peak amplitudes averaging 660% of basal (interpulse) release. The frequency was confirmed by spectral and autocorrelation analyses. The punctuated insulin-secretory bursts partially overlap and are responsible for the majority (70 +/- 4%) of insulin release. After ingestion of a mixed meal, the insulin release was increased through amplification of the secretory burst mass (507 +/- 104 vs. 1,343 +/- 211 pmol x l(-1) x min(-1), P < 0.001), whereas frequency (4.4 +/- 0.2 vs. 4.3 +/- 0.2, P = 0.86) and basal secretion (62 +/- 14 vs. 91 +/- 22 pmol x l(-1) x min(-1), P = 0.33) were unaffected. One subject with diabetes and cirrhosis had a similar insulin-secretory pattern, whereas a subject with insulin-dependent diabetes mellitus and minimal insulin release had preserved pulsatile release. A single subject was entrained to show agreement between entrained frequency and portal vein insulin oscillations. We conclude that insulin release in the human portal vein occurs at a mean periodicity of 4.4 +/- 0.2 min with a high signal-to-noise ratio (pulse amplitude 660% of basal). The impact of noise on the detected high frequency cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11832375     DOI: 10.1152/ajpendo.00516.2000

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  11 in total

Review 1.  Motivations and methods for analyzing pulsatile hormone secretion.

Authors:  Johannes D Veldhuis; Daniel M Keenan; Steven M Pincus
Journal:  Endocr Rev       Date:  2008-10-21       Impact factor: 19.871

2.  Calcineurin inhibitors acutely improve insulin sensitivity without affecting insulin secretion in healthy human volunteers.

Authors:  Lara Aygen Øzbay; Niels Møller; Claus Juhl; Mette Bjerre; Jan Carstens; Jørgen Rungby; Kaj Anker Jørgensen
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

3.  Diabetes-associated genetic variation in TCF7L2 alters pulsatile insulin secretion in humans.

Authors:  Marcello C Laurenti; Chiara Dalla Man; Ron T Varghese; James C Andrews; Robert A Rizza; Aleksey Matveyenko; Giuseppe De Nicolao; Claudio Cobelli; Adrian Vella
Journal:  JCI Insight       Date:  2020-04-09

4.  Intra- and inter-islet synchronization of metabolically driven insulin secretion.

Authors:  Morten Gram Pedersen; Richard Bertram; Arthur Sherman
Journal:  Biophys J       Date:  2005-04-15       Impact factor: 4.033

5.  Spatial and temporal coordination of insulin granule exocytosis in intact human pancreatic islets.

Authors:  Joana Almaça; Tao Liang; Herbert Y Gaisano; Hong Gil Nam; Per-Olof Berggren; Alejandro Caicedo
Journal:  Diabetologia       Date:  2015-09-16       Impact factor: 10.122

6.  Effect of the glucagon-like peptide-1 receptor agonist lixisenatide on postprandial hepatic glucose metabolism in the conscious dog.

Authors:  Mary Courtney Moore; Ulrich Werner; Marta S Smith; Tiffany D Farmer; Alan D Cherrington
Journal:  Am J Physiol Endocrinol Metab       Date:  2013-10-22       Impact factor: 4.310

Review 7.  Insulin administration: present strategies and future directions for a noninvasive (possibly more physiological) delivery.

Authors:  Elena Matteucci; Ottavio Giampietro; Vera Covolan; Daniela Giustarini; Paolo Fanti; Ranieri Rossi
Journal:  Drug Des Devel Ther       Date:  2015-06-17       Impact factor: 4.162

8.  Durable Control of Autoimmune Diabetes in Mice Achieved by Intraperitoneal Transplantation of "Neo-Islets," Three-Dimensional Aggregates of Allogeneic Islet and "Mesenchymal Stem Cells".

Authors:  Christof Westenfelder; Anna Gooch; Zhuma Hu; Jon Ahlstrom; Ping Zhang
Journal:  Stem Cells Transl Med       Date:  2017-05-03       Impact factor: 6.940

9.  Interim report on the effective intraperitoneal therapy of insulin-dependent diabetes mellitus in pet dogs using "Neo-Islets," aggregates of adipose stem and pancreatic islet cells (INAD 012-776).

Authors:  Anna Gooch; Ping Zhang; Zhuma Hu; Natasha Loy Son; Nicole Avila; Julie Fischer; Gregory Roberts; Rance Sellon; Christof Westenfelder
Journal:  PLoS One       Date:  2019-09-19       Impact factor: 3.240

10.  A mathematical model of the impact of insulin secretion dynamics on selective hepatic insulin resistance.

Authors:  Gang Zhao; Dagmar Wirth; Ingo Schmitz; Michael Meyer-Hermann
Journal:  Nat Commun       Date:  2017-11-08       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.